

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

25 March 2014

Serum Institute of India Boosts Its SoloFlow® Stock

HIGHLIGHTS:

- **950,000 SoloFlow® Non-Injection Needles ordered by Serum Institute of India ("SII") – the third order for SII**

The Board of Telezon® Limited ("the Company") is pleased to announce that the Serum Institute of India (SII) has placed a third commercial order with Telezon for supply of SoloFlow® Non-Injection Needles. SII, the world's largest producer of Measles and DTP vaccines, will use the new order of 950,000 SoloFlow® needles as a key component in their influenza vaccine kits. The vaccine kits are then distributed to the market for use in remote vaccination campaigns, areas that are almost inaccessible for even the simplest forms of healthcare.

Mr Trevor Nye, Chairman of Telezon, commented that "*This order is another demonstration of one of the markets that Telezon has been actively pursuing, which is delivering tangible, commercial outcomes. To have validation of the relevance of our products and technologies for these markets, especially from a globally influential vaccine group such as Serum Institute, is an indication of great things to come for our Company.*"

This third commercial order is extremely encouraging as it reinforces both SII's confidence in Telezon as a supplier, as well as the quality of our SoloFlow® needle for this purpose. This additional order further solidifies our ongoing relationship with SII.

For more information about SII, refer to <http://www.seruminstitute.com/>

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Co. Secretary
T: 61 03 9763 8605 F: 61 03 9763 2714